- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Jaypirca is a non covalent inhibitor targeting BTK, primarily used to treat specific types of B-cell malignancies, including relapsed/refractor...
Pirtobrutinib is a non covalent inhibitor targeting BTK, with a therapeutic focus on specific B-cell malignancies, mainly covering two indicati...
The standard dose of Anamorelin is 100mg orally per day, and the specific number of pills to be taken should be calculated based on the single ...
The recommended usage period of Anamorelin is usually no more than 12 weeks (3 months), mainly used for short-term weight management in cancer ...
The treatment schedule of Adagrasib needs to be personalized based on the treatment response and tolerance of KRAS G12C mutant non-small cell l...
The duration of medication for Adagrasib needs to be dynamically adjusted according to individual patient conditions. Clinical data shows a med...
The medication cycle of Relugolix should be determined based on the treatment indication and patient response. It is usually used for chronic d...
Relugolix, as a novel GnRH receptor antagonist, has demonstrated rapid and sustained testosterone inhibition in the treatment of prostate cance...
Futibatinib, as a highly selective FGFR inhibitor, has shown significant efficacy in solid tumors such as cholangiocarcinoma carrying FGFR2 gen...
Futibatinib, as a highly effective inhibitor targeting FGFR2 gene mutations, has shown excellent clinical efficacy in the treatment of solid tu...
